ZOLL Medical Corporation recently received FDA premarket approval for its Hospital Wearable Defibrillator (HWD). The device offers continuous protection to hospitalized patients at risk for ventricular tachycardia or fibrillation. The company cites evidence that delays in defibrillation increase mortality, as well as complications in those who survive such a crisis.
The HWD represents an additional tool for medical personnel responsible for cardiac disease patients. It facilitates staff operations and affords additional protection to patients, especially those not housed in intensive care units. The device senses dangerous arrhythmias and automatically delivers a corrective shock.
An alert is sent 60 seconds before the shock, giving conscious patients time to delay treatment. The detection algorithm and defibrillation waveform are identical to those in the company’s LifeVest Wearable Defibrillator, designed for out-of-hospital use.